An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial.
Lancet OncolSep 4, 2026 (epub)
Clinical ResearchOncology (Medical)
Liam Bourke, Derek J Rosario, Sophie Reale et al.
✦ AI-curated · Sources linked
In 30 seconds
The STAMINA trial, a multicentre, randomised study, evaluated a lifestyle intervention for men undergoing androgen deprivation therapy (ADT) for prostate cancer. The intervention, which included supervised exercise and dietary support, significantly improved cancer-specific quality of life and fatigue compared to Optimised Usual Care. The FACT-P score improved by an adjusted mean difference of 4.5.
Key findings
- The STAMINA intervention improved FACT-P scores by an adjusted mean difference of 4.5.
- FACIT-F scores increased by an adjusted mean difference of 1.9 with the STAMINA intervention.
- 89% of participants in the STAMINA group provided primary outcome data compared to 81% in the Optimised Usual Care group.
- Three serious adverse events were reported in the STAMINA group, all resolved without lasting effects.
Why it matters
This study highlights the importance of integrating lifestyle interventions into cancer care, particularly for patients on ADT, to enhance quality of life and reduce fatigue, which are critical aspects of patient management.